Today's Date: June 4, 2023
Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023   •   Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different P   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipili   •   New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing   •   Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin   •   GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting   •   Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Developme   •   High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy   •   Dorsett Wanchai Marks World Environment Day 2023 with Bold Paperless and Plastic-Free Sustainability Initiatives   •   Cupshe Celebrates 8th Birthday with Exclusive Collection in Collaboration with Chanel Iman, Heather Rae El Moussa, and Brittany   •   Tips for a smooth transition to senior living from the San Luis Obispo assisted living professionals   •   Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclit   •   Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam   •   ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Pl   •   Bijou Ikli named new CEO by Florida Assisted Living Association   •   Government of Canada releases summary of actions taken to address the safety and wellbeing of Indigenous women, girls and 2SLGBT   •   Statement by the Prime Minister on Canadian Armed Forces Day   •   Reigniting the Cancer Moonshot: Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in C   •   TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years
Bookmark and Share

Rubedo Life Sciences Presents In Vivo Efficacy Data Targeting Senescence Cells to Treat Dermatological Diseases

SAN FRANCISCO , March 20 /Businesswire/ - Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class disease-modifying therapies for chronic age-related diseases, presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases. The data was presented during the 2023 American Academy of Dermatology (AAD) conference week, a gathering of the largest, most influential, and representative dermatology group, with a membership of more than 20,500 physicians worldwide. The focus of the annual conference is to help dermatological professionals learn about the latest industry updates and research.

This press release features multimedia. View the full release here:

Ofir Moreno, Ph.D., is Senior Vice President, Drug Discovery at Rubedo, presenting at the OncoDermatology Society conference. (Photo: Business Wire)

Ofir Moreno, Ph.D., is Senior Vice President, Drug Discovery at Rubedo, presenting at the OncoDermatology Society conference. (Photo: Business Wire)

Histopathological assessment showed that Rubedo’s lead compound significantly reduced senescence signatures associated with skin senescent cells, and significantly improved skin pathophysiological manifestations, such as chronic desquamation in preclinical animal models of chemotherapy-induced skin fibrosis and dermatitis.

“We’re excited to present for the first time, efficacy data of our lead compound that compares favorably to standard of care and supports further development,” said Ofir Moreno, Ph.D., Senior Vice President, Drug Discovery at Rubedo, who presented the data at the Oncodermatology Society conference. “By targeting the pathologic cells that drive aging, our approach has demonstrated a robust response targeting a fundamental mechanism which leads to inflammatory dermatological diseases such as chronic atopic dermatitis, plaque psoriasis, and chemotherapy-induced skin fibrosis and alopecia which are common side-effects of cancer treatment, and drivers of an accelerated biological aging process.”

The Oncodermatology Society conference held on March 17 in New Orleans, was chaired by Dr. Mario Lacouture, Professor and the Director of the Oncodermatology Program in the Dermatology Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center in New York, and a Scientific Advisory Board member at Rubedo Life Sciences.

“We’re thrilled to present this data to key opinion leaders in the longevity field, ahead of our nomination of a clinical candidate for our dermatology program targeting skin senescent cell types that drive chronic degenerative dermatological conditions associated with biological aging processes,” said Marco Quarta, Ph.D., CEO & Founder, Rubedo Life Sciences.

Rubedo is planning first-in-human studies in multiple skin indications driven by chronic inflammation and degenerative fibrosis. Leveraging its proprietary single-cell multiomics platform ALEMBIC™, Rubedo identifies pathologic cells with senescence features characteristic of multiple dermatological chronic skin conditions, and is developing potent and selective compounds targeting those cells using its selective senolytic platform SenTech™.

About Rubedo Life Sciences

Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies. The company is based in Sunnyvale, CA. For additional information, visit

STORY TAGS: Photo/Multimedia, California, Research, Other Health, Pharmaceutical, Oncology, Consumer, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, Seniors, Health, Other Science, Conference, Product/Service, United States, North America,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News